Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.

ABSTRACT:

Background

In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease.

Objective

To identify other potential clinical benefits of molnupiravir versus placebo.

Design

Secondary analysis of the randomized, double-blind, placebo-controlled phase 3 component of MOVe-OUT. (ClinicalTrials.gov: NCT04575597).

Setting

107 sites globally.

Participants

1433 nonhospitalized adults aged 18 years or older with mild to moderate COVID-19.

Intervention

Molnupiravir, 800 mg, or placebo every 12 hours for 5 days.

Measurements

Changes from baseline in C-reactive protein (CRP) concentration and oxygen saturation

SUBMITTER: Johnson MG 

PROVIDER: S-EPMC9186515 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature